J. Goldman & Co’s aTyr Pharma ATYR Stock Holding History

J. Goldman & Co’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,131	Closed	-$91K	–	669
2025 Q1	$91K	Sell	30,131 -270,000	-90%	-$984K	﹤0.01%	447
2024 Q4	$1.09M	Buy	+300,131	New	+$909K	0.03%	322

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's ATYR Position: Q2 2025 in Review

J. Goldman & Co sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 30,131 shares — an estimated $91K sold.

J. Goldman & Co first reported a position in ATYR in Q4 2024 and held it in 2 quarters. The position peaked at $1.09M in Q4 2024. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

J. Goldman & Co reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
J. Goldman & Co sold 30,131 aTyr Pharma shares in Q2 2025, an estimated $91K.
J. Goldman & Co first reported a position in aTyr Pharma in Q4 2024 and held it in 2 quarters.
J. Goldman & Co's aTyr Pharma position peaked at $1.09M in Q4 2024.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.